A MicroRNA signature in pediatric ulcerative colitis: Deregulation of the miR-4284/CXCL5 pathway in the intestinal epithelium

Inflammatory Bowel Diseases

Volumn 21, Issue 5, 2015, Pages 996-1005

  Koukos, Georgios ^a   Polytarchou, Christos ^a   Kaplan, Jess L ^b   Oikonomopoulos, Angelos ^a   Ziring, David ^a   Hommes, Daniel W ^a   Wahed, Renaisa ^c   Kokkotou, Efi ^c   Pothoulakis, Charalabos ^a   Winter, Harland S ^b   Iliopoulos, Dimitrios ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSGENERAL HOSPITAL FOR CHILDREN   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

colonic epithelial cells; inflammatory bowel disease; noncoding RNA

Indexed keywords

BALSALAZIDE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; INFLIXIMAB; MESALAZINE; METRONIDAZOLE; MICRORNA; MICRORNA 4284; PREDNISONE; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; CXCL5 PROTEIN, HUMAN; MIRN4284 MICRORNA, HUMAN;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CLINICAL ARTICLE; COHORT ANALYSIS; COLON BIOPSY; CONTROLLED STUDY; DOWN REGULATION; EXPERIMENTAL COLITIS; FEMALE; GENE TARGETING; GENETIC ASSOCIATION; GENOMIC IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTESTINE EPITHELIUM; LUCIFERASE ASSAY; MALE; MOUSE; MRNA EXPRESSION ASSAY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS; 3' UNTRANSLATED REGION; ANIMAL; BIOLOGY; C57BL MOUSE; CASE CONTROL STUDY; CHILD; COMPARATIVE STUDY; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; IN SITU HYBRIDIZATION; INTESTINE MUCOSA; METABOLISM; PROGNOSIS; YOUNG ADULT;

3' UNTRANSLATED REGIONS; ADOLESCENT; ADULT; ANIMALS; CASE-CONTROL STUDIES; CHEMOKINE CXCL5; CHILD; COLITIS, ULCERATIVE; COMPUTATIONAL BIOLOGY; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; HUMANS; IN SITU HYBRIDIZATION; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84929094363     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000339     Document Type: Article

References (32)

1. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
2. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307-317.
3. Ruemmele FM, Turner D. Differences in the management of pediatric and adult onset ulcerative colitis-lessons from the joint ECCO and ESPGHAN consensus guidelines for the management of pediatric ulcerative colitis. J Crohns Colitis. 2014;8:1-4.
4. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215-233.
5. Androulidaki A, Iliopoulos D, Arranz A, et al. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity. 2009;31:220-231.
6. Iliopoulos D, Jaeger SA, Hirsch HA, et al. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell. 2010;39:493-506.
7. Dalal SR, Kwon JH. The role of MicroRNA in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2010;6:714-722.
8. Wu F, Zikusoka M, Trindade A, et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology. 2008;135:1624-1635e24.
9. Wu F, Zhang S, Dassopoulos T, et al. Identification of microRNAs associated with ileal and colonic Crohn's disease. Inflamm Bowel Dis. 2010; 16:1729-1738.
10. Zahm AM, Hand NJ, Tsoucas DM, et al. Rectal microRNAs are perturbed in pediatric inflammatory bowel disease of the colon. J Crohns Colitis. 2014;8:1108-1117.
11. Koukos G, Polytarchou C, Kaplan JL, et al. MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis. Gastroenterology. 2013;145:842-852e2.
12. Walz A, Burgener R, Car B, et al. Structure and neutrophil-Activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med. 1991;174:1355-1362.
13. Koch AE, Kunkel SL, Harlow LA, et al. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest. 1994;94:1012-1018.
14. Keates S, Keates AC, Mizoguchi E, et al. Enterocytes are the primary source of the chemokine ENA-78 in normal colon and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol. 1997;273:G75-G82.
15. Z'Graggen K, Walz A, Mazzucchelli L, et al. The C-X-C chemokine ENA-78 is preferentially expressed in intestinal epithelium in inflammatory bowel disease. Gastroenterology. 1997;113:808-816.
16. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15-20.
17. Betel D, Wilson M, Gabow A, et al. The microRNA.org resource: targets and expression. Nucleic Acids Res. 2008;36:D149-D153.
18. Berg DJ, Zhang J, Weinstock JV, et al. Rapid development of colitis in NSAID-Treated IL-10-deficient mice. Gastroenterology. 2002;123:1527-1542.
19. Christodoulou K, Wiskin AE, Gibson J, et al. Next generation exome sequencing of paediatric inflammatory bowel disease patients identifies rare and novel variants in candidate genes. Gut. 2013;62:977-984.
20. Beaudoin M, Goyette P, Boucher G, et al. Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS Genet. 2013;9:e1003723.
21. Polytarchou C, Koukos G, Iliopoulos D. Systems biology in inflammatory bowel diseases: ready for prime time. Curr Opin Gastroenterol. 2014;30: 339-346.
22. Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009; 58:1612-1619.
23. Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol. 2014;11:243-255.
24. Barnard JA. Recent advances in pediatric gastroenterology, hepatology and nutrition. F1000prime Rep. 2013;5:25.
25. Shi C, Liang Y, Yang J, et al. MicroRNA-21 knockout improve the survival rate in DSS induced fatal colitis through protecting against inflammation and tissue injury. PLoS One. 2013;8:e66814.
26. Taganov KD, Boldin MP, Chang KJ, et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006;103: 12481-12486.
27. Hatziapostolou M, Polytarchou C, Aggelidou E, et al. An HNF4alphamiRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell. 2011;147:1233-1247.
28. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NFkappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009;139:693-706.
29. Munari E, Marchionni L, Chitre A, et al. Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Hum Pathol. 2014;45:1130-1138.
30. MacDermott RP. Chemokines in the inflammatory bowel diseases. J Clin Immunol. 1999;19:266-272.
31. Buanne P, Di Carlo E, Caputi L, et al. Crucial pathophysiological role of CXCR2 in experimental ulcerative colitis in mice. J Leukoc Biol. 2007;82: 1239-1246.
32. Kwon JH, Keates AC, Anton PM, et al. Topical antisense oligonucleotide therapy against LIX, an enterocyte-expressed CXC chemokine, reduces murine colitis. Am J Physiol Gastrointest Liver Physiol. 2005;289: G1075-G1083.